Wall St futures flat amid US-China trade jitters; bank earnings in focus
HORSHAM, Pa. - STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company with $32.85 million in trailing twelve-month revenue and a market capitalization of $9.91 million, announced Thursday that partner clinics utilizing its Elevate 360 (E360) consulting services platform have experienced business growth, according to a company press release.
The E360 program, designed to help partner clinics maximize revenue potential with STRATA’s XTRAC excimer laser technology, provides marketing solutions, business system optimization, and patient retention tactics. According to InvestingPro data, the company maintains a healthy gross profit margin of 57.81%, though analysts note the company faces profitability challenges.
Since early 2025, 99 of approximately 844 clinics operating under STRATA’s XTRAC usage agreement have enrolled in the program, resulting in an average 7% year-over-year growth for participating businesses.
The company highlighted one partner that expanded from two clinics to nine after adopting the E360 program in Q3 2024. This partner’s revenue contribution to STRATA increased from $10,500 in the first half of 2024 to $61,800 in the first half of 2025. Despite these positive developments, InvestingPro analysis reveals the company is currently trading below its Fair Value, with additional insights available in the comprehensive Pro Research Report covering over 1,400 US stocks.
"We developed the E360 program to help them better utilize and expand their business operations with a goal to maximize their revenue opportunities and attract and retain patients," said Dr. Dolev Rafaeli, STRATA’s President and CEO.
The program focuses on improving the end-to-end treatment process, from identifying patient referrals and securing insurance reimbursements to scheduling treatments and follow-up visits.
STRATA Skin Sciences develops and markets medical technology for treating dermatologic conditions including psoriasis, vitiligo, and acne through its XTRAC excimer laser, VTRAC lamp systems, and TheraClearX Acne Therapy System. The company’s stock currently trades at $1.88, having declined 35.4% year-to-date, reflecting broader market challenges in the medical technology sector.
The company offers these technologies through a Partnership Program that includes a fee-per-treatment cost structure rather than equipment purchases.
In other recent news, STRATA Skin Sciences reported a 9% decline in total revenue for the second quarter of 2025, bringing in $7.7 million compared to the same period last year. Despite the revenue drop, the company expressed optimism for the latter half of the year, citing potential increases in reimbursement rates and expanded market opportunities. Additionally, STRATA Skin Sciences announced a registered direct offering of common shares, raising approximately $2.42 million. The company entered into definitive securities purchase agreements with institutional investors for 1,097,547 shares at $2.204 per share, with Ladenburg Thalmann & Co. Inc. acting as the exclusive placement agent. This offering was priced at-market under Nasdaq rules. These developments indicate ongoing strategic financial maneuvers by the company amidst fluctuating revenue figures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.